Compare Stocks

→ “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CPTRF Captor Capital	$0.17 +4.9%	$0.17	$0.08 ▼ $0.31	$9.02M	N/A	N/A	5,900 shs
ECOR electroCore	$5.65 +1.3%	$6.31	$3.83 ▼ $8.08	$33.92M	0.91	12,942 shs	12,585 shs
FBRX Forte Biosciences	$0.74 +2.8%	$0.71	$0.38 ▼ $1.15	$26.90M	0.48	32,489 shs	2,845 shs
LXRP Lexaria Bioscience		$0.22	$0.17 ▼ $0.56	$20.15M	N/A	608,350 shs	2.15 million shs

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CPTRF Captor Capital	0.00%	0.00%	0.00%	0.00%	0.00%
ECOR electroCore	+1.25%	+0.18%	-8.28%	-25.26%	-15.55%
FBRX Forte Biosciences	+4.08%	-5.26%	+6.95%	-1.11%	-30.28%
LXRP Lexaria Bioscience	0.00%	0.00%	0.00%	0.00%	0.00%

“Retirement Secret” Showed 995% Gain Last Time We Shared It (Ad)

Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.

Find out why right here (and see what you can do to get in too with just a few dollars).

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CPTRF Captor Capital	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ECOR electroCore	1.9795 of 5 stars	3.5	5.0	0.0	0.0	0.0	0.8	0.6
FBRX Forte Biosciences	3.093 of 5 stars	3.3	4.0	0.0	0.0	2.2	2.5	1.3
LXRP Lexaria Bioscience	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CPTRF Captor Capital	N/A	N/A	N/A	N/A
ECOR electroCore	3.00	Buy	$10.00	76.99% Upside
FBRX Forte Biosciences	2.50	Moderate Buy	$2.75	272.12% Upside
LXRP Lexaria Bioscience	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest LXRP, CPTRF, FBRX, and ECOR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
4/8/2024	FBRX Forte Biosciences	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$2.75
3/14/2024	ECOR electroCore	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy

(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CPTRF Captor Capital	$31.65M	0.28	N/A	N/A	$0.30 per share	0.58
ECOR electroCore	$16.03M	2.12	N/A	N/A	$1.24 per share	4.56
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	$0.97 per share	N/A
LXRP Lexaria Bioscience	$380K	0.00	N/A	N/A	$0.03 per share	0.00

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CPTRF Captor Capital	-$9.82M	-$0.27	N/A	∞	N/A	-50.42%	-91.75%	-42.26%	N/A
ECOR electroCore	-$18.83M	-$3.56	N/A	N/A	N/A	-117.49%	-201.47%	-109.61%	5/1/2024 (Estimated)
FBRX Forte Biosciences	-$31.48M	-$1.04	N/A	N/A	N/A	N/A	-94.27%	-81.36%	5/20/2024 (Estimated)
LXRP Lexaria Bioscience	-$4.09M	N/A	0.00	N/A	N/A	-1,046.77%	-157.62%	-148.09%	N/A

Latest LXRP, CPTRF, FBRX, and ECOR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
3/18/2024	Q4 2023	FBRX Forte Biosciences	N/A	-$0.04	-$0.04	-$0.04	N/A	N/A
3/13/2024	Q4 2023	ECOR electroCore	-$0.55	-$0.61	-$0.06	-$0.61	$5.23 million	$5.19 million
2/29/2024	Q3 2024	CPTRF Captor Capital	N/A	-$0.01	-$0.01	-$0.01	N/A	$6.88 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CPTRF Captor Capital	N/A	N/A	N/A	N/A	N/A
ECOR electroCore	N/A	N/A	N/A	N/A	N/A
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	N/A
LXRP Lexaria Bioscience	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CPTRF Captor Capital	N/A	1.56	1.45
ECOR electroCore	N/A	1.76	1.49
FBRX Forte Biosciences	N/A	10.45	10.45
LXRP Lexaria Bioscience	0.01	8.52	8.01

Ownership

Institutional Ownership

Company	Institutional Ownership
CPTRF Captor Capital	N/A
ECOR electroCore	26.74%
FBRX Forte Biosciences	77.63%
LXRP Lexaria Bioscience	0.11%

Insider Ownership

Company	Insider Ownership
CPTRF Captor Capital	N/A
ECOR electroCore	13.14%
FBRX Forte Biosciences	10.53%
LXRP Lexaria Bioscience	N/A

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
CPTRF Captor Capital	N/A	52.10 million	N/A	Not Optionable
ECOR electroCore	68	6.00 million	5.21 million	Not Optionable
FBRX Forte Biosciences	9	36.40 million	32.56 million	Optionable
LXRP Lexaria Bioscience	4	89.59 million	N/A	Not Optionable

LXRP, CPTRF, FBRX, and ECOR Headlines

Source	Headline
	Lexaria Bioscience ethics review board approval to begin new GLP-1 study pharmabiz.com - April 18 at 10:44 AM
	Lexaria gets ethics board okay for oral GLP-1 study msn.com - April 16 at 3:35 PM
	Lexaria (NASDAQ: LEXX) Hires Research Organization to Perform GLP-1 Human Pilot Study theglobeandmail.com - March 27 at 9:50 AM
	Lexaria appoints Nelson Cabatuan as CFO msn.com - March 14 at 12:59 PM
	Lexaria Bioscience (NASDAQ: LEXX) Banking on DehydraTECH(TM) for Major 2024 Growth theglobeandmail.com - March 11 at 12:04 PM
	Lexaria Bioscience Corp.: Lexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules finanznachrichten.de - February 16 at 6:06 PM
	Why Lexaria Bioscience (LEXX) Shares Are Moving msn.com - February 15 at 12:03 PM
	Lexaria Bioscience Corporation seeks US FDA nod to begin phase 1b hypertension trial HYPER-H23-1 of DehydraTECH-CBD pharmabiz.com - February 1 at 12:01 AM
	Lexaria Unveils Extensive Planned 2024 GLP-1 Study Program finance.yahoo.com - January 16 at 9:48 AM
	Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream finance.yahoo.com - January 11 at 8:53 AM
	Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through ... bakersfield.com - January 9 at 10:32 AM
	LEXX: GLP-1s’ Sweet Opportunity msn.com - November 30 at 1:27 PM
	Lexaria's Technology Lowers Blood Glucose More Effectively than Rybelsus-Branded GLP-1 drug Semaglutide Alone in Human Pilot Study thenewswire.com - November 28 at 1:26 PM
	Lexaria's Technology Improves the Oral Performance of the Rybelsus-Branded GLP-1 drug Semaglutide in Human Pilot Study thenewswire.com - November 27 at 12:25 PM
	Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Studies of Proprietary Platform in Multibillion-Dollar GLP-1 Drug Space finance.yahoo.com - November 1 at 9:17 AM
	Lexaria Bioscience’s Growth Prospects: New Licensing Agreement, Advanced Core Pipeline, and Positive Clinical Trials markets.businessinsider.com - October 18 at 7:59 PM
	Lexaria Enters New Global Exclusive Collaboration and License Agreement with SulfoSyn finance.yahoo.com - October 13 at 10:35 AM
	DehydraTECH-powered GLP-1 drugs will be evaluated for potential improvements such as: thenewswire.com - September 21 at 9:50 AM
	Lexaria Bioscience (NASDAQ: LEXX) Expands Portfolio in Oral Nicotine Delivery Sector msn.com - August 5 at 8:21 PM
	Lexaria Bioscience Corp.: Lexaria's Plans to Study Weight Loss and Diabetes Control in a Human Clinical Study with DehydraTECH-CBD finanznachrichten.de - August 2 at 9:39 AM
	Lexaria's Plans to Study Weight Loss and Diabetes Control in a Human Clinical Study with DehydraTECH-CBD bignewsnetwork.com - August 2 at 9:39 AM
	Lexaria Bioscience (NASDAQ: LEXX, LEXXW) Announces New Subsidiary, Provides Update on Nicotine Study theglobeandmail.com - July 29 at 2:55 AM
	Lexaria Bioscience Corp.: Lexaria Incorporates New Subsidiary for CPG Products and Updates Human Nicotine Study finanznachrichten.de - July 28 at 11:53 AM
	Lexaria Incorporates New Subsidiary for CPG Products and Updates Human Nicotine Study finance.yahoo.com - July 28 at 11:53 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Captor Capital

OTCMKTS:CPTRF

Captor Capital Corp. engages in the manufacture and retail sale of cannabis products in the United States. It operates two dispensaries under the CHAI Cannabis Co. brand in Santa Cruz and Monterey, California, as well as operates an e-commerce site under the CHAI-brand. The company was formerly known as NWT Uranium Corp. and changed its name to Captor Capital Corp. in June 2017. Captor Capital Corp. was incorporated in 2003 and is based in Toronto, Canada.

electroCore

NASDAQ:ECOR

electroCore, Inc., a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga for the support of general health and wellbeing; and TAC-STIM for human performance. In addition, the company offers gammacore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.

Forte Biosciences

NASDAQ:FBRX

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

Lexaria Bioscience

OTCMKTS:LXRP

Lexaria Bioscience Corp. operates in the drug delivery platform business. It develops and out-licenses its DehydraTECH technology for the delivery of bioactive compounds that promotes healthy ingestion methods, lower overall dosing, and higher effectiveness in active molecule delivery. The company has licensed DehydraTECH to various companies operating in the nicotine, pharmaceutical, nutraceutical, and vitamin industries. Lexaria Bioscience Corp. was founded in 2004 and is headquartered in Kelowna, Canada.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial